Blog

  • Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Stephen O’Brien on 2014-06-05.

    To ask the Secretary of State for Transport, what estimate he has made of the number of people who will move home as a result of the construction of High Speed 2 because of (a) demolition for construction of the line and (b) blight.

    Stephen Hammond

    There are 464 dwellings within the area currently subject to surface-level safeguarding for the London to West Midlands section of HS2, of which 339 are to be demolished. Given recent Census data showing an average 2.3 occupants per property in the UK, we expect around 1,000 people will move from those homes.

    We have not estimated numbers of people who may move for reasons of generalised property blight, but there are approximately 220 dwellings within the Voluntary Purchase Area for the London to West Midlands Route announced on 9 April. Our aim is where possible to avoid serious impacts on local residents and enable people to remain in their homes. We expect to consult shortly on further measures that may make that choice more attractive for homeowners.

    Pending future decisions on routes and designs, we have made no similar estimates for other proposed sections of HS2.

  • Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Stephen O’Brien on 2014-06-05.

    To ask the Secretary of State for Transport, how High Speed 2 improve reliability and reduce overcrowding on regional links between towns and cities in the North West.

    Mr Robert Goodwill

    By moving long distance passengers off the existing network, HS2 will release capacity for more regional services, reducing overcrowding and improving reliability, as well as improving connectivity. Nationally, the Economic Case for HS2 found that HS2 will deliver reliability benefits worth £5.5bn, and reduced crowding benefits of £7.5bn, which includes benefits to regional services in the North West.

    In response to recommendations made by Sir David Higgins, HS2 Ltd and Network Rail have been commissioned to consider what further improvements can be made to centre to city centre connectivity, east-west links and local connectivity in the Midlands and the North, with a final report on options in 2015.

  • Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Stephen O’Brien on 2014-06-05.

    To ask the Secretary of State for Transport, how he expects High Speed 2 to reduce overcrowding at London Waterloo.

    Mr Robert Goodwill

    High Speed 2 is not intended to reduce overcrowding at London Waterloo, as it has been designed as a link between London Euston, Birmingham, Leeds and Manchester.

    The 2012 Rail Investment Strategy (HLOS) has asked the industry to provide additional peak capacity for 9,700 extra passengers into Waterloo by 2019 and has provided funding for Network Rail to expand Waterloo and other stations. Network Rail and South West Trains have set out plans to lengthen peak trains and South West Trains is now in discussions with the Department for Transport.

  • Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    Stephen O’Brien – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Stephen O’Brien on 2014-06-05.

    To ask the Secretary of State for Transport, with reference to the Answer of 28 April 2014, Official Report, columns 517-8W, on railways: passengers, what the evidential basis is for the stated forecast of increases in passenger numbers on the West Coast Main Line over the next 10 years.

    Stephen Hammond

    Chapter 4 of Network Rail’s West Coast Route Utilisation Strategy describes the evidential basis and modelling approach of the anticipated changes in demand to 2024-25 which are contained in the same document. This is now available at:

    http://www.networkrailmediacentre.co.uk/imagelibrary/downloadMedia.ashx?MediaDetailsID=4675

    “

  • Susan Elan Jones – 2014 Parliamentary Question to the HM Treasury

    Susan Elan Jones – 2014 Parliamentary Question to the HM Treasury

    The below Parliamentary question was asked by Susan Elan Jones on 2014-06-05.

    To ask Mr Chancellor of the Exchequer, what steps he is taking to ensure that Natwest and other subsidiaries of RBS remain as competitive as possible in the banking sector.

    Andrea Leadsom

    On 1 November 2013, RBS committed to a new direction, focussing on its core British business, supporting British families and companies. RBS’s new direction is supported wholeheartedly by the Bank of England, UKFI and the Government.

    RBS and its subsidiaries retain their own independent boards and management teams for strategic and operational decision-making.

    The Government’s shareholding in the Royal Bank of Scotland (RBS) is managed on a commercial and arm’s length basis by UK Financial Investments Ltd (UKFI).

  • Debbie Abrahams – 2014 Parliamentary Question to the Department for Transport

    Debbie Abrahams – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Debbie Abrahams on 2014-06-05.

    To ask the Secretary of State for Transport, what recent discussions he has had with train operating companies in Greater Manchester on last minute reductions in train configurations.

    Stephen Hammond

    The franchise agreement between the Government and each individual train operator includes benchmarks in key performance areas. The Department monitors each train operator’s overall performance against these areas every four weeks and there are clear actions set out in the franchise agreement should performance drop below what is expected. This regular monitoring includes monthly meetings with their senior management where performance figures are scrutinised and challenged.

    Short-forming (last minute reductions in train configurations) is included in this monitoring, and therefore in the monthly meetings. It is the train operator that decides on whether a service is to be short-formed, and if contractual benchmark figures are breached, the Department does take enforcement action.

    Some services in Greater Manchester are sponsored and specified by Transport for Greater Manchester, who also monitor the performance of the operators concerned.

  • Mary Creagh – 2014 Parliamentary Question to the Department for Transport

    Mary Creagh – 2014 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Mary Creagh on 2014-06-05.

    To ask the Secretary of State for Transport, if he will publish a breakdown by firm of expenditure by his Department on (a) consultants and (b) consultancy firms in each of the last four years.

    Stephen Hammond

    Information requested will be deposited in the library and provides the spend details per financial year for the period 2010 to 2014.

  • Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.

    Jane Ellison

    The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

    Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

    The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

    National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

    Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

    The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

  • Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    Oliver Colvile – 2014 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.

    Jane Ellison

    The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.

    Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.

    The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.

    National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.

    Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.

    Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.

    The Government’s Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.

  • Oliver Colvile – 2014 Parliamentary Question to the Cabinet Office

    Oliver Colvile – 2014 Parliamentary Question to the Cabinet Office

    The below Parliamentary question was asked by Oliver Colvile on 2014-06-05.

    To ask the Minister for the Cabinet Office, how many people died from prostate cancer in (a) Plymouth, Sutton and Devonport constituency and (b) England in each of the last five years.

    Mr Nick Hurd

    The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.